Description:
As one of the largest and fastest-growing segments in the in vitro diagnostics (IVD) industry, infectious disease testing is crucial for detecting and identifying pathogens, pinpointing their origins, and determining appropriate antimicrobial therapies.
Kalorama Information’s Infectious Disease Diagnostic Testing: World Market Analysis, 2022 examines market drivers, including external influences that promote the development and use of improved infectious disease diagnostics. The report highlights the global nature of infectious diseases and their impact on both developing and industrialized countries as long-term factors such as aging populations and the increasing burden of infectious diseases strain healthcare resources worldwide.
Report Highlights:
- Product Types: Infectious disease IVD products include reagents, consumables, and instruments based on immunoassays, molecular technologies, and conventional microbiology techniques. Tests are available for detecting hundreds of pathogenic conditions.
- Applications Analyzed:
- Healthcare-associated and opportunistic infections
- Antimicrobial-resistant pathogens (bacteria, fungi, parasites, viruses)
- Human immunodeficiency virus (HIV) and hepatitis viruses
- Women’s health and sexually transmitted infections (STDs)
- Emerging, neglected, and tropical disease threats
- Respiratory tract infections and respiratory viruses (including COVID-19)
Geographic and Country Markets:
- Regions Covered:
- North America
- Eastern Europe
- Western Europe
- Asia/Pacific
- Africa/Middle East
- Central and South America
- Other Regions
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Global Infectious Disease IVD Products Demand, by Type, 2026-2031 (in millions $)
| Type | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR |
| Sexually Transmitted Infections (STIs) | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Healthcare-Associated Infections (HAIs) | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| ID/AST | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Hepatitis | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| HIV/AIDS | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Influenza | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Tuberculosis | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| ToRXH | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Other Infections | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total World (w/o COVID-19) | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| COVID-19 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total World | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
